Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...
The NDA is supported by data from the EXCALIBER-RRMM trial, which evaluated the safety and efficacy of iberdomide, an investigational cereblon E3 ligase modulator.
Recent regulatory actions from the FDA, including new drug application (NDA) acceptances and labeling updates, introduce new clinical considerations for oncology nurses and advanced practice providers ...
Zacks Investment Research on MSN
FDA accepts BMY's NDA for iberdomide combo in multiple myeloma
Bristol Myers Squibb BMY announced that the FDA has accepted the new drug application (NDA) for its pipeline candidate, iberdomide, in combination with standard therapies (daratumumab and ...
Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II) For over half a ...
IGD (Institute of Grocery Distribution) has announced a new insight programme called, ‘IGD Futures: GLP‑1’, to help food industry businesses understand, navigate, and capitalise on the impacts of ...
IGD is launching a new insight programme to help food companies navigate the impact of GLP-1 weight-loss medication. The IGD Futures: GLP-1 programme will aim to help food industry businesses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results